id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-330640-6ityxc64	Gupta, Ashim	Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective	2020-08-11		.txt	text/plain	5159	245	37	In the case of pneumonia, acute lung injury (ALI) [12] , acute respiratory distress syndrome (ARDS) [13, 14] and sepsis studies investigating therapy using mesenchymal stem cells (MSCs) have demonstrated safety and some positive effects on these conditions [11] . Another study demonstrated that the efficacy of MSC-based therapy is enhanced with lipid conjugated heparin coating; and the human adipose derived stem cells (hADSCs) delivered to the damaged liver resulted in significantly improved recovery from ALF in a mouse model. Majority of the studies focusing on MSC-derived exosomes have demonstrated regenerative potential, immune-modulatory functions, anti-inflammatory effects, similar to their parents, i.e. Mesenchymal stem cells [44, 45] . In preclinical set up, MSC-derived exosomes have demonstrated aptitude as an acellular alternative to cell-based therapy, against Acute Respiratory Distress Syndrome (ARDS) [46] . Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Inluenza A (H7N9) infection: A hint for COVID-19 treatment.	./cache/cord-330640-6ityxc64.txt	./txt/cord-330640-6ityxc64.txt